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Collagenous colitis is a recent cause of chronic diarrhea. Cooccurrence with spondylarthropathy is rare. We describe two cases: one
man and one woman of 33 and 20 years old were suﬀering from spondylarthropathy. They then developed collagenous colitis, 4
and 14 years after the onset of spondylarthropathy. The diagnosis was based on histological features. A sicca syndrome and vitiligo
were observed with the female case. The presence of colitis leads to therapeutic problems. This association suggests a systemic kind
of rheumatic disease of collagenous colitis.
1.Introduction
The collagenous colitis (CC) is a clinicoanatomic entity
of recent individualization which was described for the
ﬁrst time in 1976 by Lindstr¨ om [1]. In the past, CC was
thought to be a rare disorder, and very little was known
about its etiology or epidemiology. Many recent publications
have shown that the incidence of CC is increasing [2].
A number of autoimmune diseases were reported to be
associated with CC, in 17 to 40% of the cases [3]. However,
spondylarthropathy (SpA) associated with CC has rarely
been reported before. Here, we describe two cases of CC in
two patients treated for an ankylosing spondylitis (AS).
2. Case Presentation
2.1. Case 1. Mrs KZ, aged 33, consulted in 1996 for a diﬀuse
rachialgia associated with an inﬂammatory left fessalgie
evolving since 10 years. There were no peripheral joint
manifestations. The X plain radiography of the pelvis was
normal. CT scan showed bilateral sacroiliitis. The HLA typ-
ing had found a haplotype A2\B40\B45. Thus, the diagnosis
of SpA was established according to the ESSG criteria (Euro-
pean Spondylarthropathy Study Group). The patient was
treated with nonsteroidal anti-inﬂammatory drugs (NSAID)
with amendment of the pains. One year later, a chronic
watery diarrhea with abdominal pains had occurred. The
colonoscopy as well as the bacteriological and parasitolog-
ical examinations of the stools was normal. However, the
colic biopsy showed a typical aspect of CC: a thickened
subepithelial collagen layer whose thickness was greater
than ten microns, increased intraepithelial lymphocytes,
and inﬂammation in the lamina propria consisting mainly
of lymphocytes and plasma cells. Other associated extra-
articular manifestations were also noted: an ocular sicca
syndrome conﬁrmed by the Schirmer test (normal salivary
biopsy of glands) and a vitiligo of the hands and forearms.
The NSAIDs were then stopped, and the patient was treated
with sulfasalazine (SLZ) associated with corticosteroids (10
milligrams of equivalent prednisone/day) with resolution
of the enteric symptoms and marked improvement of
the joint disease, as proven by the BASDAI score which
decreased from 8 to 4. In the year 2000, a symmetrical
polyarthritis of the large and small joints in the lower limbs
appeared. No radiological erosion had been detected and
the immunological investigation (rheumatoid factor and
antinuclear antibodies) remained negative. The patient did
not have a concomitant diarrheic ﬂare-up. A treatment with
NSAIDs, SLZ, and a low dose of corticosteroids, and then
with methotrexate (10 and 15mg per week) were attempted
but with no positive response. Because of the resistance
to conventional therapies, TNF alpha inhibitor was then2 Case Reports in Medicine
started. The patient received at ﬁrst inﬂiximab at a dose of
3mg/kg then at 5mg/kg every 8 weeks. The response was
excellent, however, and at the 12th perfusion, the patient
developed a toxidermia conﬁrmed by a skin biopsy, thus
motivating the switch to etanercept. After 3 months, the
disease remained active (BASDAI at 8). A second switch
towards adalimumab is currently underway.
2.2. Case 2. Mr BA, 20-year-old, was followed for a juvenile
SPA (at the age of 16) with sacroiliitis and bilateral coxitis.
Besides,HLAtypingwasnotperformed.In1999,thatis,four
years after the beginning of his disease, the patient’s disease
wasactiveunderNSAIDwithaBASDAIat6.Atthattime,the
patient also developed a sudden onset of persistent diarrhea,
made of watery but not bloody stools. Colonoscopy was
unremarkable. Systematic colonic biopsies had revealed a
thickened subepithelial collagen layer and diﬀuse inﬂamma-
tion of the lamina propria with prominent intraepithelial
lymphocytic inﬁltration, ﬁndings consistent with CC. The
NSAIDs were stopped and SLZ was started at a dose of
3g/day, resulting in a marked clinical improvement with a
BASDAI score at 3.5 after 3 months. Since then, the patient
no longer had diarrhea with a current decline of 11 years.
3. Discussion
The CC is one of the rare causes of chronic diarrhea. Clin-
ically, it is characterized by watery, chronic, and nonbloody
diarrhea. Its diagnosis, however, remains histological and the
microscopic examination of mucosal biopsies reveals char-
acteristic histopathological changes: an abnormal thickening
of the subepithelial collagen layer (>10µm ) ,a sw e l la sa
lymphocytic inﬁltration of the epithelium and the lamina
propria [4]. The etiology of CC remains enigmatic and is
multifactorial with diﬀerent elements being more inﬂuential
in diﬀerent individuals. Recent data point to a diﬀerentiation
abnormality in the colonic mucosa ﬁbroblasts, although the
exact mechanism that initiates this abnormality remains
unknown. In this regard, levels of inﬂammatory mediators
are increased in the setting of CC. These include metal-
loproteinases, growth factors (transforming growth factor
and vascular endothelial growth factor), cytokines, nitric
oxide, and prostaglandins [5]. Currently, responsibility of
several drugs has been questioned, some with strong clinical
and/or histological evidence suggesting causality. Thus, a
paper had proposed a scoring system for drug-induced
microscopic colitis, in this case CC, adapting existing
criteria of drug causality and review the literature using
this framework. Based on this paper, NSAID was identiﬁed
with high likelihood of inducing CC [6]. This etiology had
been considered in our ﬁrst case. Indeed, the time course
favors drug eﬀect since diarrhea occurred right after starting
NSAIDs and this treatment was then stopped. However,
NSAID can themselves induce diarrhea as an adverse eﬀect,
and the coexistence of CC with NSAID usage might in fact
be coincidental. Immune mechanisms seem clearly to be
involved in the pathogenesis of CC. Evidence includes the
ﬁnding of epithelial damage closely related to the increase of
CD8 TcR alpha beta intraepithelial lymphocytes [5], and the
abnormal surface membrane expression of class II major his-
tocompatibility complex (HLA-DR) on the colonic epithelial
cells [7]. A higher prevalence of antinuclear antibodies has
alsobeenfoundinpatientswithCCcomparedwithahealthy
controlpopulation[8].TheresponseofCCtocorticosteroids
also supports the hypothesis that autoimmune mechanisms
may be involved. In addition, a high proportion of patients
with CC have one or more autoimmune disorders, as in
our cases. However, the association with a sicca syndrome
can be explained by an excess of collagen. Indeed, in a
prospective study of 7 cases of CC, four patients had sicca
syndrome and the histological ﬁnding of the salivary glands
w a sc o n s i s t e n tw i t ha ne x c e s so fc o l l a g e n[ 9]. Actually, in
a retrospective study of 163 cases of CC, an associated
autoimmune disease was observed in 40% of cases [10]:
these particularly dealt with rheumatoid arthritis (n = 16),
autoimmunethyroiditis(n = 14),celiacdisease(n = 14)and
ﬁ n a l l yd i a b e t e sm e l l i t u s( n = 9). In a recent large analysis of
171 case of CC, thyroid disease, celiac disease, rheumatoid
arthritis, Raynaud/CREST syndrome were found to have
a signiﬁcantly higher occurrence in CC compared to the
control group [11]. This association was also reported with
the systemic lupus erythematosus [12, 13] and the systemic
sclerosis [14–16]. Some cases of erosive synovitis associated
with CC have been described but seem rare and non-
speciﬁc. A literature search revealed other reports of CC
with peripheral seronegative arthritis, at least 20 cases of
oligoarthritis or polyarthritis, and 2 cases of monoarthritis
[10, 17–19]. Other ﬁndings have shown a higher frequency
of this arthritis, of the order of 7% [20]. Most of the
authors actually consider this joint disease as an enteropathic
arthritis, as observed with the other inﬂammatory bowel
disease [21]. Nevertheless, the association of a CC with an
authentic SpA remains exceptional. To our knowledge, only
11caseswhomettheESSGclassiﬁcationcriteriaforSpAwere
reported in the literature (Table 1)[ 3, 17, 18, 21–27].
The SpA, when associated with CC, is characterized by
high frequency of the axial and peripheral involvement, as
seen in our ﬁrst case. Even if CC is more prevalent in women
of about ﬁfty, there is no female predominance [2]. The CC
may precede, occur concomitantly or follow-up the disease
joint [3]. In our two patients, the gastrointestinal manifes-
tation occurred 4 and 14 years after the onset of SpA. The
HLA-B27 is present in half the cases. The synovitis is usually
nonerosive, nondeforming, and seronegative [3], although
2 cases of erosive arthritis have been reported (two men,
aged 51 and 58, respectively, suﬀering from asymmetrical
polyarthritis).
The joint disease usually responds to NSAIDs, SLZ, and
low dose of oral glucocorticoids [3] but no well-codiﬁed
treatment regimen is set. NSAIDs could induce a digestive
ﬂare in analogy with chronic inﬂammatory bowel diseases
and raise a major therapeutic problem. Diﬀerent treatments
of the CC have been tried. At present, budesonide has the
best-documented eﬃcacy in treating active CC but there is
a high relapse rate when medication is tapered or ceased
[28]. SLZ has also been used with some positive results as
seen in our two patients. Immunosuppressive agents, suchCase Reports in Medicine 3
Table 1: Characteristics of the 11 cases with CC and SpA and ours patients.
Reference Sex Age Peripheral joint involvement Axial involvement Extra intestinal features Erosive
synovitis HLA B27
[21] W 33 Symmetric oligoarthritis Sacroiliitis Hypothyroidism sicca
syndrome Raynaud 0+
[18] M 58 Asymmetric polyarthritis Sacroiliitis Psoriasis 0 −
[24] W 51 0 Sacroiliitis 0 0 +
[25] M 79 Symmetric oligoarthritis Sacroiliitise Psoriasis 0 NS
[17]M 5 1 Asymmetric polyarthritis +
Dactylitis + Enthesopathy
Sacroiliitis + lumbar and
cervical ankylosis +
atlantoaxial subluxation
Hypothyroidism Vitiligo + −
[22] M 58 Asymmetric polyarthritis Cervical ankylosis Psoriasis + −
[26]W 4 8 D i ﬀuse arthralgias Sacroiliitis 0 0 −
[27]M 4 6 Symmetric oligoarthritis +
Dactylitis + Enthesopathy Sacroiliitis 0 0 +
[3] W 37 Asymmetric oligoarthritis Sacroiliitis + lumbar ankylosis 0 0 +
[3] M 47 Asymmetric oligoarthritis Sacroiliitis 0 0 −
[23] W 53 Symmetric polyarthritis 0 R e t r o b u l b a rn e u r i t i s+
Psoriasis 0+
Our case 1 W 33 Symmetric polyarthritis Sacroiliitis Sicca syndrome + Vitiligo 0 −
Our case 2 M 20 0 Sacroiliitis + spine ankylosis 0 0 NS
NS: not studied; W: woman; M: man.
as 6-mercaptopurine, azathioprine, and methotrexate are
usually considered in those patients who are refractory to or
dependent on steroids [5]. Recently,anti-TNF therapies were
eﬀective in CC with severe symptoms refractory to standard
medical therapy [29]. To the best of our knowledge, our ﬁrst
case is the ﬁrst report of using TNF alpha blocker in the
association of CC and SpA, with eﬀectiveness of antibodies
and a failure of the soluble receptor, as is typically observed
in inﬂammatory bowel disease.
4. Conclusion
The two observations highlighted above show that the CC
may be associated with various autoimmune diseases. The
entanglement of the CC to an authentic SpA and a vitiligo
suggests autoimmune mechanisms common to these con-
ditions. This association, albeit rare, deserves to be known
because of therapeutic implications.
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